Postoperative pulmonary complications in the ENIGMA II Trial: A post hoc analysis.

2023-01-16

Peyton, Philip J

Liskaser, Grace

Ho, Alexander

Marsh, Harry

Etherington, Christopher

Torlot, Freddie

Desai, Manisha

Perrett, George

Chee, Brian

Leslie, Kate

Myles, Paul S

Journal Article

0000-0003-1185-2869

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1097/ALN.0000000000004497

Nitrous oxide (N2O) promotes absorption atelectasis in poorly ventilated lung segments at high inspired concentrations. The ENIGMA Trial found a higher incidence of postoperative pulmonary complications (PPCs) and wound sepsis with N2O anesthesia in major surgery compared to FIO2 0.8 without N2O. The larger ENIGMA II trial randomised patients to N2O or air at FIO2 0.3 but found no effect on wound infection or sepsis. However, postoperative pulmonary complications were not measured. In the current study we collected post hoc data to determine if atelectasis and pneumonia incidences were higher with N2O in patients who were recruited to the Australian cohort of ENIGMA II.

link

Anesthesiology 2023-04-01; 138(4)

Anesthesiology

1528-1175